Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2025 09:00 ET | Source: XOMA Royalty Corporation

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its...
November 21, 2025 07:45 ET | Source: XOMA Royalty Corporation

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

XOMA Royalty Completes Acquisition of LAVA Therapeutics. Brings 2 partnered assets into XOMA Royalty's milestone and royalty portfolio.
November 12, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty’s announced expected acquisition of LAVA Therapeutics. Company acquisitions:...
October 17, 2025 11:45 ET | Source: XOMA Royalty Corporation; LAVA Therapeutics N.V.

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The...
October 02, 2025 16:43 ET | Source: XOMA Royalty Corporation; LAVA Therapeutics

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

XOMA Royalty extends its tender offer for LAVA Therapeutics.
September 22, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty announces October 2025 dividend
September 17, 2025 09:00 ET | Source: XOMA Royalty Corporation

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

XOMA Royalty closes tender offer for HilleVax.
September 03, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief...
August 20, 2025 08:49 ET | Source: XOMA Royalty Corporation

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty...
August 13, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA...